Climb Bio Stock Price, News & Analysis

Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 16). Most events will feature fireside chats or presentations along with one-on-one investor meetings.

Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.

Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 10). Most events will feature fireside chats or presentations along with one-on-one investor meetings.

Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.

Climb Bio (Nasdaq: CLYM) reported Q2 2025 financial results and provided significant pipeline updates. The company has advanced its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL antibody.

Key developments include: First patients dosed in both ITP and SLE trials for budoprutug, upcoming initiation of pMN Phase 2 trial, development of a subcutaneous formulation with promising non-clinical data, and advancement of CLYM116 toward clinical development for IgAN. The company appointed Edgar D. Charles, M.D. as Chief Medical Officer.

Financial highlights: $187.4 million in cash and equivalents as of June 30, 2025, with runway through 2027. R&D expenses increased to $6.6 million from $1.0 million year-over-year, while G&A expenses were $4.1 million.

Climb Bio (NASDAQ: CLYM) has strengthened its leadership team with two key appointments. Edgar D. Charles, M.D., MSc joins as Chief Medical Officer, bringing over 20 years of experience in immunology-focused pharmaceutical development from Bristol Myers Squibb and Merck. Dr. Charles, who previously served as VP and Senior Global Program Lead for Immunology at BMS, will oversee the clinical development of budoprutug and CLYM116 programs. Additionally, Cindy J. Driscoll, MBA, joins as Senior Vice President of Finance, bringing 20+ years of biotech industry experience, including successful IPOs and public financings exceeding $450 million. As part of their appointments, Dr. Charles and Ms. Driscoll received inducement equity awards of 600,000 and 200,000 stock options respectively, priced at $1.20 per share with a four-year vesting schedule.

Climb Bio (NASDAQ: CLYM) has granted an inducement equity award to a new employee under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The award, granted on May 19, 2025, consists of a non-statutory stock option to purchase 120,000 shares of common stock at an exercise price of $1.27 per share, matching the closing price on Nasdaq Global Market. The option has a ten-year term and vests over four years, with 25% vesting after the first year and the remaining shares vesting in 36 monthly installments, contingent on continued employment.

Climb Bio (NASDAQ: CLYM) reported its Q1 2025 financial results and provided key business updates. The company's lead program budoprutug, an anti-CD19 monoclonal antibody, is advancing with FDA clearances for clinical trials in multiple indications. Clinical studies for ITP and SLE are set to begin in H1 2025, followed by pMN trials in H2 2025.

The company expanded its pipeline with CLYM116, an anti-APRIL monoclonal antibody licensed from Mabworks for IgA nephropathy treatment. Climb Bio strengthened its leadership by appointing two new independent directors and a Chief Business Officer. Financially, the company reported $197.8 million in cash and equivalents, expected to fund operations through 2027. R&D expenses increased to $17.3 million in Q1 2025, including a $9.0 million upfront payment to Mabworks.

Climb Bio (Nasdaq: CLYM) has announced significant changes to its Board of Directors with the appointments of two biotech industry veterans: Kim Cobleigh Drapkin, CPA, and Bo Cumbo. Drapkin, who will serve as Audit Committee Chair, brings over 30 years of financial leadership experience in biotech and pharmaceutical companies, most recently serving as CEO of Graphite Bio.

Cumbo, appointed as Compensation Committee Chair, has 30+ years of experience in the pharmaceutical and biotechnology industries, with a track record of leading 11 successful specialty and rare disease therapy launches. He currently serves as President and CEO of Solid Biosciences.

The appointments come as Climb Bio positions itself for evolution into a late-stage, pre-commercial company focused on immune-mediated diseases. Concurrent with these appointments, Simon Tate will step down from the Board, and Adam Rosenberg will not seek re-election at the 2025 Annual Meeting.

Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's executive team will be presenting at this virtual event, which is scheduled to take place from April 7-10, 2025.

The presentation is specifically scheduled for April 10, 2025, at 8:45 a.m. ET. The format will include both a formal presentation and one-on-one investor meetings, providing opportunities for direct engagement with the company's leadership.

Climb Bio (NASDAQ: CLYM) reported its Q4 and full-year 2024 financial results, marking significant progress in its immune-mediated disease therapeutics pipeline. The company secured FDA clearance for clinical trials of budoprutug in three indications: Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE).

The company expanded its pipeline by in-licensing CLYM116, an anti-APRIL monoclonal antibody for IgA Nephropathy treatment. Financial highlights include a strong cash position of $212.5 million as of December 31, 2024, expected to fund operations through 2027. The company reported a net loss of $73.9 million for full-year 2024, compared to $35.1 million in 2023, with the increase primarily due to $51.7 million in acquired research and development expenses.